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Abstract: Cystic Fibrosis (CF) is the most common fatal inherited disease of Caucasians, affecting about 1 in 3000 births. 
Patients with CF have a recessive mutation in the gene encoding the CF transmembrane conductance regulator (CFTR). 
CFTR is expressed in the epithelium of many organs throughout the exocrine system, however, inflammation and damage 
of the airways as a result of persistent progressive endobronchial infection is a central feature of CF. The inflammatory 
response to infection brings about a sustained recruitment of neutrophils to the site of infection. These neutrophils release 
various pro-inflammatory compounds including proteases, which when expressed at aberrant levels can overcome the 
endogenous antiprotease defence mechanisms of the lung. Unregulated, these proteases can exacerbate inflammation and 
result in the degradation of structural proteins and tissue damage leading to bronchiectasis and loss of respiratory function. 
Other host-derived and bacterial proteases may also contribute to the inflammation and lung destruction observed in the 
CF lung. Antiprotease strategies to dampen the excessive inflammatory response and concomitant damage to the airways 
remains an attractive therapeutic option for CF patients. 
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INTRODUCTION 
  Cystic Fibrosis (CF) lung disease is characterised by 
progressive chronic infection and inflammation of the 
airways. The lungs of patients with CF contain elevated 
levels of neutrophils and proinflammatory cytokines such as 
tumour necrosis factor- (TNF-), interleukin (IL)-6 and IL-
8, as well as reduced levels of the anti-inflammatory 
cytokine IL-10 [1, 2]. This inflammatory response is largely 
orchestrated by the respiratory epithelium. These cells are 
part of the first line of defence against pathogens and are 
responsible for the release of several pro-inflammatory 
mediators such as IL-8, which acts as a neutrophil 
chemoattractant [3]. Once recruited to the airways, the 
neutrophils are primed and activated releasing various 
compounds such as proteases, oxidants, DNA, and cationic 
proteins in order to clear the bacteria [4]. When released in 
excessive amounts, these molecules can cause damage to the 
respiratory epithelium resulting in yet more pro-
inflammatory cytokine release [5-7]. In particular, serine 
proteases such as neutrophil elastase (NE) enhance the 
inflammatory response when they are released at the 
epithelial surface. This results in increased IL-8 expression 
and further neutrophil influx thereby creating a cycle of 
inflammation. This cycle of airway inflammation, in 
conjunction with reduced mucus clearance, is responsible for 
the mucopurulent plugging and bronchiectasis commonly 
seen in the diseased CF lung [8]. 
  In order to engage in bacterial phagocytosis neutrophils 
have to be primed, and in the case of CF, TNF- and IL-8  
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are known to play a key role in this activation [9]. When 
neutrophils are activated in this fashion they release more NE 
than neutrophils from healthy controls [9]. In addition, these 
primed and activated CF neutrophils are resistant to the anti-
inflammatory affect of IL-10. Once neutrophils have migrated 
to the site of infection and are primed and activated, they can 
begin the process of bacterial phagocytosis. The environment of 
the CF lung however provides several challenges to efficient 
bacterial phagocytosis. The acidic environment of the CF 
airway surface due to non-functioning CFTR can result in 
neutrophil necrosis being favoured over neutrophil apoptosis 
following bacterial phagocytosis, ultimately resulting in greater 
damage to the lung [10]. In addition, the hyperviscous mucus 
found in CF airways severely hampers efficient neutrophil 
phagocytosis and is thought to increase the incidence of 
infection by organisms such as by Pseudomonas aeruginosa, 
Staphylococcus aureus, and Haemophilus influenzae. The 
predominant organism to colonise the CF lung in the early 
stages is S. aureus. Although it responds well to antibiotic 
therapy,  S. aureus is thought to leave the lung vulnerable to 
colonisation by pseudomonads [11]. Unlike S. aureus, P. 
aeruginosa has a greater potential to resist antibiotic therapies 
and over time to become the predominant organism in the CF 
infected lung [11]. When infection with P. aeruginosa in the CF 
lung becomes persistent the local density of the population 
increases resulting in the release of quorum-sensing compounds 
such as N-acyl homoserine lactones. This quorum-sensing leads 
to a coordinated switch from nonmucoid to mucoid alginate 
producing P. aeruginosa [12]. The resulting biofilm formation 
results in the colonising P. aeruginosa becoming even less 
susceptible to antibiotic therapies and neutrophil clearance. 
Excessive accumulation of neutrophils at the site of biofilm 
formation may also result in self damage via release of oxidants 
and proteolytic enzymes [13]. Antiproteases as Therapeutics to Target Inflammation in Cystic Fibrosis  The Open Respiratory Medicine Journal, 2010, Volume 4    21 
  The main source of protease activity in the CF lung is 
thought to be activated neutrophils, however, the role of 
proteases derived from other cell sources, such as 
mononuclear and epithelial cells, as well as exogenously 
derived bacterial proteases may also play a vital role in 
mediating destruction of the lung as seen in CF (as illustrated 
in Fig. 1). The main emphasis
  of this review will be to 
address the role of these endogenous and exogenous 
proteases and describe past, present and future developments 
in the search for an efficient antiprotease therapy in CF. 
SERINE PROTEASES 
Neutrophil Elastase (NE) 
  Neutrophils are responsible for the release of proteolytic 
enzymes such as matrix metalloproteases (MMPs) and the 
serine protease NE, all of which are capable of destroying 
the extracellular matrix (ECM). NE plays a key role in the 
pathophysiology of CF making it one of the major 
determinants of the pulmonary inflammatory phenotype. NE 
is a 29 kDa serine protease produced in the neutrophil and 
stored in primary azurophilic granules for secretion upon 
activation, phagocytosis and cell death. Although the normal 
role of NE is to degrade phagocytosed proteins, if it is 
released from the neutrophil and breaches the lungs 
antiprotease defences it has the potential to degrade most of 
the structural proteins of the lung including elastin, 
fibronectin and other proteins of the ECM [14]. The cleavage 
of cell surface fibronectin in particular allows improved 
adherence of P. aeruginosa to the cell facilitating the 
colonisation of the CF lung. Degradation of opsonic proteins 
and C3b receptors on the surface of neutrophils has also been 
shown to significantly reduce the efficacy of antibody 
mediated phagocytosis [15, 16]. Elevated levels of NE in the 
CF lung can prevent resolution of inflammation which 
normally occurs by the removal of apoptotic neutrophils 
from the airway by macrophages [17]. 
  In the presence of NE, there is reduced apoptotic cell 
removal as a consequence of NE cleavage of the 
phosphatidylserine receptor, CD36, and various other 
apoptotic cell recognition receptors on macrophages [18]. 
NE can also prolong the inflammatory response by 
degrading complement resulting in the release of C5a, which 
acts as a chemoattractant for neutrophils [15]. Increased 
neutrophil recruitment can also be brought about by the 
direct effect of NE on the epithelium resulting in the release 
of IL-8 [19]. The accumulation of neutrophils in the airway 
can also result in elevated oxygen radical production, airway 
cell death, and increased leukotriene B4 leading to even 
greater neutrophil recruitment. NE can also cause a reduction 
in the ciliary beat frequency of the respiratory epithelium and 
an increase in serous cell mucus production, which hinder 
bacterial clearing from the lung [20]. NE is known to 
exacerbate lung inflammation and injury via  its interplay 
with the potentially damaging MMPs. MMP-9 can be 
directly activated by NE or indirectly by inactivation of 
tissue inhibitor metallopeptidase-1 (TIMP-1) the endogenous 
inhibitor of MMP-9 [21, 22]. The activation of MMP-2 by 
NE is also possible via a mechanism that requires expression 
of MMP-14 [23]. 
Cathepsin G 
  Cathepsin G is a chymotrypsin-like serine protease stored 
in primary azurophilic granules within neutrophils and is 
secreted upon activation. It possesses broad-range specificity 
for substrates and is capable of degrading the structural 
proteins of the ECM. It also plays a role in the inhibition of 
apoptotic cell clearance from CF airways via the removal of 
cell receptors from the surface of macrophages [24]. 
Furthermore, cathepsin G along with NE can activate the 
protease-activated receptor (PAR) family, in particular the 
PAR-2 receptor. However, cathepsin G and NE can also 
inactivate PAR-2 preventing its activation by trypsin [25]. 
 
Fig. (1). The importance of the balance between proteases and antiproteases in CF airways. The overwhelming of the airway innate 
antiprotease shield by excessive and dysregulated secretion of host and bacterial proteases in the CF lung leads to exacerbation of the 
inflammatory response and lung damage. 
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Surfactant
 protein A (SP-A), a pattern recognition molecule 
that facilitates
  uptake of microbes by macrophages and 
neutrophils was shown to be degraded by protease-
containing bronchoalveolar lavage fluid (BALF) from CF 
patients and this degradation could be abrogated by the 
addition of serine protease inhibitors [26]. The degradation 
was directly attributed to cathepsin G, NE and proteinase-3 
although  cathepsin G demonstrated the highest potency 
against SP-A [26]. 
Proteinase 3 
  Proteinase 3, a serine protease secreted by activated 
neutrophils, also plays a role in the inflammatory response. 
Proteinase 3 can cleave the mature form of IL-8 to a more 
active truncated form [27, 28]. This truncated form of IL-8 
has a 20-fold increased ability to act as a chemoattractant 
compared to wild type [27, 28] and also induces increased 
degranulation and intracellular calcium mobilisation in 
neutrophils and enhances interaction with the CXC 
chemokine receptor 1 [28]. Active proteinase 3 is present in 
CF sputum and its concentration was found to be highly 
correlated with the concentration of taurine present, which is 
a reliable marker of airway inflammation and respiratory
 
scores [29]. It is postulated that the unregulated deleterious 
activities of proteinase 3 could be prevented by treatment 
with the serine protease inhibitor alpha-1-antitrypsin (AAT) 
[30]. 
Endogenous Serine Antiproteases 
  The release of proteolytic enzymes during the 
inflammatory response has enormous potential to exacerbate 
and prolong inflammation causing numerous deleterious 
effects such as lung tissue destruction and reduced bacterial 
clearance. To counteract this, the airways are equipped with 
a highly regulated antiprotease shield to dampen and control 
excessive proteolytic activity. The protease-antiprotease 
imbalance hypothesis of chronic neutrophil-mediated lung 
disease contends that this imbalance, or overwhelming of the 
natural antiprotease defence mechanisms, determines 
pulmonary phenotype [31]. Several CF studies have 
correlated protease lung burden with disease severity and 
have shown an inverse relationship to the status of the 
antiprotease defence shield [7, 32-34]. The function of the 
airway antiprotease defence system is to inhibit the activity 
of cognate proteases thereby preventing potentially 
damaging degradation of host tissue (Fig. 1). The primary 
antiproteases of the airway are AAT, secretory leucoprotease 
inhibitor (SLPI), elafin, TIMPs and cystatins [31, 35-38]. 
The primary protease targets of AAT, SLPI and elafin are 
the serine proteases, NE, proteinase 3 and cathepsin G, all of 
which are released by activated neutrophils [30, 31, 35, 36]. 
Alpha-1 Antitrypsin (AAT) 
  The AAT gene is located on chromosome 14 (q31-32.3), 
spanning 12.2 kb and consisting of seven exons and six 
introns [39]. The coding exons (II-V) follow three exons (Ia, 
Ib, Ic), which code for the untranslated region of the AAT 
gene [40, 41]. The gene is translated into a 418 amino acid 
protein incorporating a 24 amino acid signal peptide. 
Glycosylation of AAT occurs at three asparagine (ASN) sites 
- ASN 46, 83 and 247 - in the endoplasmic reticulum and the 
protein is packaged in the Golgi apparatus prior to release. 
The final 52 kDa protein is produced primarily in 
hepatocytes but has also been shown to be expressed in 
epithelial cells, macrophages and neutrophils [42-44]. Due to 
the large number of AAT mRNA transcripts present in the 
hepatocyte, it is believed that serum AAT is largely derived 
from the liver from where it diffuses throughout the body 
and into the lung. In addition to its role in regulating serine 
protease activity, AAT is also known to be involved in 
regulating the inflammatory response via  several 
mechanisms unrelated to its antiprotease activity. The 
increase in cAMP levels brought about by AAT activation of 
adenylate cyclase and classic downstream activation of 
cyclic AMP-dependent protein kinase (PKA) by cAMP can 
inhibit endotoxin-stimulated TNF- and IL-10 production in 
human monocytes [45]. 
  AAT is a member of the serpin family of serine protease 
inhibitors [46]. The tertiary structure of members of this 
family is similar, as is the exposed reactive centre loop 
containing the inhibitory active site sequence [47]. AAT 
inhibits many proteases including trypsin, plasmin, 
thrombin, factor X and cathepsin G [41]. However, the main 
cognate protease of AAT is NE. When NE binds to the 
active site of AAT, the Met358-Ser359 bond, cleavage of 
this Met-Ser bond results in the generation of a tight, non-
covalent interaction between NE and AAT thereby inhibiting 
NE activity and causing release of the 36-amino acid C-
terminal Ser359-Lys394 peptide [48]. The oxidation 
susceptibility of AAT renders it less active against NE. The 
association rate constant of AAT drops from 6 x 10
-7 M
-1s
-1 
to 3 x 10
-4 M
-1s
-1, a drop of almost 2000-fold [49]. The 
molecular basis of this oxidation was initially shown to be 
oxidation of the active site Met358 residue [50]. However, 
using recombinant-derived AAT, it has since been 
demonstrated that Met351, another active site residue, is also 
involved in the AAT-NE interaction [51]. 
  There are nine methionine residues present in the AAT 
sequence, however, only Met 351 and 358 are fully surface 
exposed and thereby bind to NE. In the case of porcine 
pancreatic elastase (PPE), only Met358 appears to be 
important for binding to, and inhibiting, this protease [52]. 
The differences in binding of oxidised AAT to NE and PPE 
can most likely be explained by the previous observation that 
oxidised AAT is a much less potent inhibitor of NE although 
it will still bind and inhibit NE albeit at a much slower rate. 
However, oxidised AAT does not inhibit PPE indicating that 
the inhibitory mechanisms of AAT for PPE and NE are 
different [49, 53]. 
Secretory Leucoprotease Inhibitor (SLPI) 
  SLPI was initially identified as a serine protease inhibitor 
present in a number of bodily secretions including nasal, 
bronchial, salivary, tear and seminal secretions [54-57]. The 
SLPI gene is 2.65 kb in length and is composed of four 
exons and three introns [58]. The mature protein is 11.7 kDa 
in size, consisting of 107 amino acids and comprising two 
domains [59]. Each domain is homologous to the whey acid 
protein (WAP) motif, a protein sequence composed of 4 
disulfide bridges and approximately 50 amino acids in length 
[60]. SLPI and elafin are the best characterised of the WAP 
family of proteins, which currently stands at 15 members, 
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[60]. Readers are directed to many excellent reviews on the 
structural and multifunctional activities of these proteins [61-
65]. Expression sites for SLPI are found primarily in 
mucosal tissue but it can also be produced by inflammatory 
cells including macrophages and neutrophils [66, 67]. SLPI 
has been shown to inhibit NE, cathepsin G, chymotrypsin 
and trypsin [59]. Interestingly, SLPI does not inhibit the 
other neutrophil serine protease, proteinase 3, in contrast to 
AAT and elafin [68]. Due to its high association rate 
constant for NE, SLPI is considered to be the major inhibitor 
of NE in the upper respiratory tract. 
  Recent research has shown that SLPI possesses 
antibacterial properties, which may be important in front-line 
defence of the upper airways. In addition to its antiprotease 
and antibacterial properties, it has been shown that SLPI also 
possesses anti-inflammatory activity [61-66, 69]. In response 
to LPS, SLPI deficient mice show increased mortality from 
endotoxin shock [70]. Furthermore, in a mouse model of 
acute lung injury, prior administration of SLPI decreased 
lung injury and down-regulated nuclear factor (NF)-B 
activation by preventing degradation of the NF-B inhibitor 
protein, IB [71, 72]. It has also been shown that SLPI is 
capable of entering cells and localising in both the cytoplasm 
and nucleus, where it binds directly to NF-B binding sites 
in a site-specific fashion [73]. However the anti-
inflammatory and antiprotease properties of SLPI have been 
found to be greatly reduced when SLPI is oxidised leaving 
free NE capable of causing lung tissue injury and 
inflammation [74, 75]. 
  The crystallographic structure of SLPI reveals a 
boomerang-like shape with an N-terminal domain of 
residues 1-54 and a C-terminal domain composed of residues 
55-107 (Table 1) [76]. The antiprotease active site of SLPI 
has been located on a loop (residues 67-74) on the C-
terminal domain containing the scissile bond Leu72-Met73. 
As with AAT, the association rate constant of SLPI for NE is 
very high (10
-7 M
-1s
-1) and the rate of dissociation is low and 
contains an active site methionine residue (Met73), which is 
susceptible to oxidative inactivation, rendering it a less 
effective antiprotease [77]. It has also been shown that the 
Thr67-Tyr68 bond of the active site loop is susceptible to 
cleavage by members of the elastolytic cathepsin family, 
cathepsin B, L and S [78]. Recent studies strongly suggest 
that cathepsins play a putative role in the cleavage of SLPI in 
emphysema resulting in decreased SLPI levels and activity 
[78]. In studies of individuals with community-acquired 
pneumonia, SLPI levels were found to be increased in the 
infected and uninvolved lobes, in comparison to lobes in 
healthy controls [74]. The overall anti-NE activity in 
infected BALF was low consistent with evidence of SLPI 
cleavage in infected BALF samples [74]. These studies show 
that while SLPI levels can increase in certain disease states 
in response to infection, activity can be compromised by 
proteolytic cleavage. 
Elafin 
  The mature form of elafin is a 6 kDa protein possessing a 
WAP domain homologous to the WAP domains present in 
the SLPI protein, and is found in bronchial secretions and in 
the skin [35, 36, 79, 80] (Table 1). Elafin is expressed by 
many cell types present in the lung but also by endothelium 
and alveolar macrophages [36, 81, 82]. The elafin gene is 2.3 
kb in length, composed of three exons and two introns, and 
possesses transcription factor binding sites for AP-1 and NF-
B [36, 83, 84]. Elafin is expressed as a 117 amino acid 
protein, which includes a 22-residue signal peptide [36]. 
Both TNF- and IL-1 have been demonstrated to induce 
elafin expression in pulmonary epithelial cells although LPS 
does not [84]. The primary function of elafin is the inhibition 
of the neutrophil serine proteases NE and proteinase 3 but 
not cathepsin G [35, 85]. In contrast, SLPI inhibits cathepsin 
G but not proteinase 3 [68]. 
  As with SLPI, elafin is a potent inhibitor of NE with an 
association rate constant of 3.6 x 10
-6 M
-1s
-1. Other activities 
of elafin have been described. For example, overexpression 
of elafin improves acute lung injury induced by P. 
aeruginosa in mice although it is not clear if this affect is 
dependent on the antiprotease activity of elafin or an 
antibacterial/anti-inflammatory affect [86]. Recently, it has 
been demonstrated that pre-elafin can protect against LPS-
induced lung inflammation in mice by decreasing neutrophil 
influx into the lung, decreasing gelatinase activity and 
reducing levels and expression of a number of pro-
inflammatory mediators [87]. A study looking at the status of 
elafin in CF sputum found that elafin was cleaved in sputum 
from individuals with CF [88]. P. aeruginosa-positive 
sputum, which contained lower levels of elafin and higher 
levels of NE, was found to be particularly effective at 
cleaving recombinant elafin [88]. In vitro incubation of 
recombinant elafin with excess NE resulted in rapid cleavage 
of elafin at two cleavage sites at the N-terminal end of elafin 
[88]. These cleavage products were still able to inhibit NE 
but they had diminished ability to bind LPS and were less 
readily immobilised by transglutamination [88]. 
Table  1.  Comparison of the Structure and Function of the Serine Protease Inhibitors SLPI and Elafin, Two Closely Related 
Members of the WAP Family of Proteins 
 
Structure/Function SLPI  Elafin 
Size  11.7 kDa (117 amino acids)  6 kDa (57 amino acids) 
WAP domains  2  1 
pI 9.5    9.7 
Anti-protease activities  Neutrophil elastase, cathepsin G, chymase, trypsin, chymotrypsin  Neutrophil elastase, proteinase 3 
Anti-bacterial  E. coli, P. aeruginosa, S. aureus  P. aeruginosa, S. aureus 
Anti-inflammatory Inhibits  NF-B activation and cytokine production  Inhibits NF-B and AP-1 activation and cytokine production 24    The Open Respiratory Medicine Journal, 2010, Volume 4  Quinn et al. 
THERAPEUTIC SERINE ANTIPROTEASE APPROACHES 
  A large variety of lung diseases are characterised by the 
presence of multiple unopposed protease activities (serine 
protease, MMPs and cathepsins). Lung tissue is susceptible 
to the direct effect of proteolysis in addition to its effect on 
other soluble host defence proteins present on the respiratory 
surface. As lung tissue is susceptible to the direct and 
indirect effects of these proteases it would seem reasonable 
to hypothesize that antiprotease therapy directed against 
these activities would be of benefit. Small synthetic 
inhibitors based on the active sites of many of the naturally 
occurring antiproteases are currently being tested in animal 
models [89-92]. However, some of these inhibitors possess 
certain drawbacks - decreased half-life, increased toxicity 
and the induction of an immune response - that may limit 
their use. In addition, many of these inhibitors have not yet 
been tested in humans. Much of the clinical work in this area 
has centred on the use of recombinant and plasma-purified 
versions of the naturally-occurring antiproteases, particularly 
AAT and SLPI. 
Therapeutic Application of AAT 
  AAT augmentation therapy with plasma-purified AAT 
has been available for the treatment of AAT deficiency since 
1987. Intravenous administration of plasma-purified AAT 
augments serum and lung levels of AAT and increases anti-
elastase capacity in individuals deficient in AAT [93, 94]. A 
study into the clinical application of AAT in CF 
demonstrated a fall in NE activity brought about by AAT 
augmentation therapy, however bacterial loading in the 
sputum of CF patients was unaltered [95]. A further double-
blinded, randomised, placebo-controlled trial demonstrated 
that aerosolised recombinant AAT (rAAT) was safe and well 
tolerated by CF patients [96]. However, no significant 
difference between rAAT and placebo for NE sputum 
activity was observed, though some secondary efficacy 
variables such as myeloperoxidase levels were improved 
[96]. A trial determining the effects of AAT aerosol therapy 
on airway inflammation in CF also observed no change in 
sputum NE activity. However levels of sputum taurine - 
which is known to correlate with CF respiratory 
exacerbations - did show a progressive decrease during the 
therapy, suggesting that even in the absence of elastase 
inhibition, AAT aerosol activity may have a beneficial effect 
on airway inflammation [97]. 
  A randomised study of CF patients receiving a daily 
deposition of AAT targeting either the peripheral or 
bronchial compartment demonstrated increased levels of 
AAT and decreased levels of NE activity and other 
endpoints such as neutrophil infiltration, pro-inflammatory 
cytokines and P. aeruginosa numbers in the lung [98]. 
Despite the anticipation that peripheral AAT deposition 
might be superior to bronchial deposition, no significant 
difference was seen between the two approaches in regards 
to NE activity and several other parameters [98]. A recent 
study has looked to improve the efficacy of AAT by 
addressing some of the key factors of aerosol administration 
such as reproducibility of delivered dosage both inter- and 
intra-patient and that the dose be deposited at therapeutic 
levels in the correct region of the lung despite differing 
levels of disease severity [99]. Using individually adapted 
breathing patterns, where both the airflow rate and inhalation 
were controlled for each subject, they achieved 70% total 
lung deposition of the AAT filling dose in all three 
populations studied (healthy, AAT deficient and CF) [99]. 
  Despite this work, aerosolised rAAT administration 
remains problematic since delivery to the diseased lung via 
this method is uneven with ‘less diseased’ sites being 
favoured over ‘diseased’, also it is deposited on the mucus 
layer rather than at the cell surface [100]. In addition, 
administration of rAAT is less effective because of the 
relatively impermeable nature of the epithelium to 
macromolecules [101]. To overcome these limitations, a 
more targeted delivery system would prove advantageous. A 
recent study has shown that it is possible to effectively target 
AAT to the apical surface of human tracheal xenografts via a 
fusion protein with a single-chain Fv directed against the 
extracellular portion of polymeric immunoglobulin receptor 
(pIgR) [100]. This targeted approach should be amenable to 
the use of other antiproteases or anti-inflammatory agents. 
Therapeutic Application of SLPI and Elafin 
  Recombinant SLPI (rSLPI) has also been administered to 
individuals with CF resulting in decreased active NE and 
decreased IL-8 levels on the epithelial surface of the lung. 
The latter effect is partly due to the ability of SLPI (and 
AAT) to inhibit NE-induced up-regulation of IL-8 by the 
respiratory epithelium [102-104]. Pharmacokinetics of 
aerosolised rSLPI show that while SLPI levels and anti-
elastase capacity are increased in the epithelial lining fluid of 
CF patients and healthy controls post-aerosolisation, rSLPI 
did not accumulate on the respiratory epithelial surface 
[103]. Although administration of SLPI and AAT may prove 
useful in neutralising serine protease activity in neutrophil-
dominated lung diseases, they may have little effect on the 
other non-serine proteases present on the epithelial surface. 
Therefore, a combined antiprotease therapeutic strategy 
using cystatins and TIMPs as well as serine protease 
inhibitors, may prove to be a most useful way to combat 
protease-mediated lung destruction. A double-blind, 
randomised, placebo-controlled Phase I clinical trial of elafin 
demonstrated that intravenously applied doses were well 
tolerated in healthy male subjects. Although elafin is in the 
development pipeline as a therapeutic, no data from CF-
related studies has yet been published to our knowledge 
[105]. 
Application of Synthetic Protease Inhibitors 
  DX-890 (also known as EPI-hNE4) has been developed 
as a NE inhibitor [106]. However, although postulated to be 
proteolytically stable, this inhibitor has been shown to be 
only partially effective in neutralising NE activity in 
Pseudomonas-infected CF sputum probably due to 
degradation by pepsin [107]. In addition, it has not been 
tested against NE at higher molar NE:DX-890 ratios (i.e. 2:1 
and higher), which would be more representative of in vivo 
CF lung conditions. Alternatively, many companies have 
developed low molecular weight synthetic inhibitors of NE. 
In addition to GSK’s activity in this area, acyl-enzyme 
inhibitors (ONO-5046, L-694458 and MR-889) and 
transition-state inhibitors (ONO-6818, AE-3763 and FK-
706), all potent NE inhibitors, have been evaluated in 
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Pharmaceutical to name only a few. Yet, none of these 
compounds have shown sufficient promise to make it to the 
market. For instance, Ono had conducted a phase IIa double 
blind clinical study (low and high doses of ONO-6818 vs 
placebo) in patients with COPD in Japan since July, 2001, 
but it voluntarily suspended the study due to abnormal 
elevation of liver function test values and deferred the 
commencement of the U.S. phase II study [108]. Crucially, 
these synthetic compounds, being mechanism-based 
inhibitors, do not possess any other additional antibacterial 
and anti-inflammatory properties such as the endogenous 
inhibitor SLPI. 
OTHER HOST-DERIVED PROTEASES 
  The airway disease in CF is characterised by chronic 
infection and an inflammatory response dominated by 
infiltrating neutrophils and therefore much of the work to 
date has focused on neutrophil serine proteases as key 
players in mediating lung damage, and corresponding serine 
protease inhibitors as potential therapeutics, as discussed 
previously. Although serine proteases and NE in particular 
predominate in CF [31], it is nevertheless important to 
recognise that a broad range of extracellular proteases from a 
variety of cell types also contribute to pulmonary damage 
seen in CF. Thus, the role and interplay of other protease 
families as well as the role of their respective inhibitors 
when contemplating antiprotease therapy must be 
considered, areas often neglected in terms of antiprotease 
therapy in CF. Indeed, it is evident from the published work 
available that a number of complicated cascades of protease 
activity exists in CF and other chronic infective lung 
diseases that may further compound the already arduous task 
of designing efficient antiprotease therapy. Our 
understanding of the roles of other protease families such as 
the cysteine cathepsins and metalloproteases is incomplete 
and perhaps impaired due to degeneracies that exist in 
protease function and cell to cell variation in specific roles. 
Thus, further study into the specific roles played by 
individual proteases in CF is much needed in order to 
develop efficient antiprotease therapies for CF. 
Cysteine Cathepsins 
  The term cathepsin is given to a number of proteases 
from various families including cysteine cathepsins (B, C, H, 
L, S, K, O, F, X, V and W), aspartic proteases (cathepsins D 
and E), serine proteases (A and G), and metalloproteases 
(cathepsin III). For the purpose of this section, the potential 
of cysteine cathepsin inhibitors as therapeutics in CF will be 
discussed. Evidence is emerging that various members of 
this family of lysosomal proteases are over-expressed and 
secreted in the diseased lung by a variety of lung cells and 
infiltrating inflammatory cells, comprehensively reviewed in 
[37, 109, 110]. Cathepsins are synthesised as inactive 
preproenzymes, and while they are directed towards
  the 
lysosomal compartment, some cells can secrete significant 
amounts of mature
 and procathepsins [109, 110]. Thus, many 
cathepsins can degrade components of the ECM 
intracellularly and extracellularly, and cathepsins K, L, and S 
are among the most potent elastases known [111]. 
  In the lungs, a number of cathepsins are expressed 
ubiquitously,
 e.g. cathepsins B, H and L, whereas others are 
expressed
 either in macrophages (cathepsin S) or in bronchial 
epithelial
  cells (cathepsin K) and type II pneumocytes 
(cathepsin H) [112-114]. Most cathepsins are unstable at 
neutral pH and have only weak activity in such environments 
and instead work at an acidic pH, with the exception of 
cathepsins S and C, which retain their activity in neutral pH 
conditions [115, 116]. The pH of epithelial lining fluid in CF 
is 5.8, decreasing to as low as 5.3 during infective 
exacerbations [117]. Thus, the acidic environment in the 
lungs of patients with CF provides optimal conditions for 
cathepsin activity and highlights the importance of 
therapeutic interventions directed at regulating this activity. 
There is also evidence for the interplay between NE and 
cathepsins in inflammation whereby NE up-regulates
 
expression of cathepsin B and may play an important role in 
the activation of this enzyme [118, 119]. We and others have 
shown previously that activities of cathepsins such as B, L, 
H and S are increased in lung secretions and serum from 
patients with CF, compared with those in BALF from 
healthy individuals [119-122]. 
 NE  up-regulates
  expression of cathepsin B in 
macrophages and increased cathepsin B levels were observed
 
in wild-type mice compared with NE knockout mice 
challenged
 with P. aeruginosa [118]. However, like serine 
proteases, lysosomal cysteine proteases appear to play an 
important role in regulating the innate immune response. 
Cathepsin C (dipeptidyl aminopeptidase 1), which is found 
highly expressed in the lung, was shown to activate the 
granule-associated serine proteases NE, cathepsin G, 
granzymes A and B, and mast cell chymase in vitro and in 
vivo [123-125]. These findings suggest the existence of yet 
another protease cascade highlighting the intricate 
relationship that exists between proteases. Cathepsins have 
been found to contribute significantly to the destruction of a 
number of host defence proteins which exhibit antimicrobial, 
antiprotease and immunomodulatory potential. Johnson et al 
[126] reported the ability of cathepsin L to inactivate AAT, 
one of the major
 serine protease inhibitors present in the lung 
discussed previously. Furthermore, cleavage and inactivation 
of SLPI and the antimicrobial human -defensins 2 and 3 
and lactoferrin by cathepsins B, L, and S has also been 
reported [78, 120, 121]. Taken together,
  these findings 
indicate the involvement of cathepsins in the diminution
 of 
the lung antiprotease and antimicrobial screen possibly 
leading to lung destruction and favouring conditions for 
bacterial infection and colonisation. 
  The activity of cathepsins
 is of course regulated tightly at 
different levels, given their exceptional proteolytic activity 
and
  the high concentration of cathepsins (up to 1  mM) in 
lysosomes. Endogenous inhibitors called cystatins regulate 
their activity. Cystatins are expressed
 intracellularly (type 1 
cystatins or stefins; cystatins A and B) or extracellularly 
(type 2 cystatins; cystatins
 C, D, S, SA, SN, E/M and F) [37, 
110]. Serine proteases can cleave
  and inactivate protease 
inhibitors such as cystatin
 C, again highlighting interaction 
between proteases, because
  serine protease inactivation of 
cysteine protease inhibitors
  increases the likelihood of free 
cathepsin activity
 [127]. 
  The presence of secreted cathepsins in the lung may be 
necessary
 to regulate the activities of these cationic proteins 
and peptides; however,
  this process may become 
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antiprotease/anti-inflammatory
  screen and thereby 
perpetuating inflammation and infection. Although the 
presence of elevated cathepsin activity has been reported in 
CF, little or no data on the levels of corresponding 
endogenous inhibitors is available. Without similar increases 
in protease inhibitor concentrations, the tight regulation 
required to keep these powerful proteases in check may 
contribute to an overall imbalance between proteases and 
protease inhibitors. Overall, these findings suggest that 
dysregulated cysteinyl cathepsin activity may play an 
important role in the pathogenesis and progression of CF 
lung disease, providing sound evidence for the need of 
further research into potential antiprotease therapies directed 
either against these proteases or via  increasing levels of 
endogenous inhibitors, research areas which to date has been 
severely neglected. A number of cathepsins have been 
validated as relevant targets for therapies for a diverse range 
of diseases including cancer and osteoarthritis, and 
compounds targeting cathepsins S and K are currently in 
clinical evaluation, whereas others are in experimental 
phases [128]. As cysteine cathepsins continue to emerge as 
important components of CF lung disease, there is potential 
for agents such as these to be applied to CF research in the 
future. 
MATRIX METALLOPROTEASES (MMPs) 
  In CF lung disease,
  another major protease group of 
interest are the MMPs. To date, 24 mammalian MMPs have 
been described and there appears to be considerable overlap 
in the substrates that these enzymes can cleave, particularly 
among the ECM proteins
  [129, 130]. MMPs are either 
secreted as latent pro-enzymes or anchored to the cell surface 
and MMPs can be classified in part on their substrate 
specificity and in part on their cellular localisation; the 
collagenases (MMP-1, -8, -13 and -18), gelatinases (MMP-2 
and -9), stromelysins (MMP-3, -10 and -11), membrane-type 
MMPs (MMP-14-17, MMP-24 and -25), matrilysin (MMP-7 
and -26), metalloelastase (MMP-12), but there are a number 
of MMPs that don’t fit into any of these groups. 
  MMP synthesis and function are tightly controlled by a 
family of endogenous inhibitors called TIMPs. To date, 4 
have been identified, TIMP-1, -2 and -4, are secreted, while 
TIMP-3 is anchored in the ECM. Many cell types produce 
MMPs and TIMPs in the lung, including epithelial (MMP-1, 
-2, -9, TIMP-1 and -2), smooth muscle cells (MMP-2, -3, -7, 
MMP-14/MT1-MMP, TIMP-1 and -2), neutrophils (MMP-8, 
-9 and TIMP-1), alveolar macrophages (MMP-1, -9, -12 and 
TIMP-1), and mast cells (MMP-9) [38]. Typically, MMPs 
are not expressed in normal healthy tissues. However, while 
increased levels of MMP-2, -7, -8 and -9 in CF BALF and 
serum have been documented, conflicting data on the levels 
of TIMP-1 in CF lung secretions has been reported [122, 
131-135]. As previously mentioned, evidence exists for the 
interplay between NE and MMPs, as NE activates MMP-9 
directly but also indirectly by inactivating TIMP-1,
  the 
naturally occurring inhibitor of MMP-9 [22, 136].
 
Furthermore, NE may activate MMP-2 through a mechanism 
that
  requires MMP-14 expression or by directly affecting 
gene expression [23, 118]. 
  Similar to what has been found with serine and cysteine 
protease families, MMPs regulate the turnover of the ECM, 
but also act broadly in inflammation to regulate barrier 
function, innate immunity, and inflammatory cytokine and 
chemokine activity [17, 28, 137]. Similar to members of the 
serine and elastolytic cathepsin families, a number of MMPs 
are capable of degrading a wide variety of soluble proteins
 
present on the respiratory tract. Serine proteases can cleave
 
and inactivate protease inhibitors such as TIMP-1 increasing 
the likelihood of free MMP activity
 [20]. Likewise, a large 
number of MMPs (MMP-1, -3, -7,
 -8, -9, and -12) can cleave 
and inactivate AAT,
 thereby allowing NE, cathepsin G, and 
proteinase 3 to remain
  active [138-142]. In addition, 
Ramadas  et al. [143] recently reported the ability of 
recombinant MMP-12 to cleave recombinant SLPI, however, 
no evidence for this event in vivo was reported. In contrast, 
both SLPI and elafin are resistant to proteolytic inactivation 
by MMP-2, -8 and -12 [143, 144]. 
  Another related group of proteases that may play a role in 
CF is
  the ADAM ("a disintegrin and metalloprotease") 
family of proteases that includes proteins containing 
disintegrin-like and metalloprotease-like domains. ADAMs 
are typically distributed over the bronchial epithelium and in 
inflammatory cells suggesting a localised function [145]. As 
most ADAMs are involved in release of inflammatory 
mediators, growth factors and mucin, they may play an 
important role in the first line of defence and in initiation of 
repair events in the airways [145]. However, little or no 
information exists on the status and integrity of these 
proteases in the CF lung. Two of the most prominent 
ADAMs are TNF- converting enzyme (TACE, ADAM17) 
and ADAM10. Again, interplay between NE and this family 
of proteases exists as NE can activate TACE thereby 
facilitating the induction of MUC5AC mucin expression 
[146]. Mucus hypersecretion is a prominent manifestation in 
patients with CF and contributes significantly to the 
morbidity and mortality of CF patients by plugging airways 
and causing recurrent infections. MUC1 plays a critical
 role 
in protecting mucosal epithelia from microbial and 
enzymatic
 attack and MUC1 shedding is controlled by TACE 
and MMP-14 [147, 148]. MUC1 has also been shown to act
 
as an adhesion site for Pseudomonas, an interaction that is
 
abolished by proteolytic cleavage by NE, suggesting a 
possible
  role for this protein in binding and removal of 
bacteria [149]. 
PROTEASOME-RELATED PROTEASES 
  Recently other protease-mediated pathways which are 
implicated in CF pathogenesis have come to light. The most 
common disease causing mutation of CF, F508del, causes 
mutant CFTR to be rapidly destroyed by endoplasmic 
reticulum (ER)-associated degradation (ERAD), which acts 
as a quality system for protein folding [150]. The ERAD 
system is responsible for the ubiquitination and subsequent 
destruction of misfolded proteins via  the ubiquitin-
proteasome system. The deletion of a phenyalanine at 
position 508 of the CFTR results in a temperature-sensitive 
folding defect and premature degradation via  the ERAD 
system [151]. The proteasome, which is responsible for the 
proteolytic degradation of ubiquitinated proteins, can be 
inhibited by the drug bortezomib which is a potent, 
reversible and selective inhibitor of chymotryptic threonine 
protease activity [152]. Recent work has shown that 
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appearance of mature CFTR and functional chloride 
channels [150]. A reduction of IL-8 expression levels via 
proteasomal inhibition was also demonstrated [150]. 
However, this favourable anti-inflammatory effect may 
come at the expense of a reduction in normal proteasomal 
degradation. 
BACTERIAL PROTEASES 
  The secretion and control of host proteolytic species has 
been shown to be pivotal in the pathology of the diseased CF 
lung. Initially bacterial proteases were thought of as merely 
secreted digestive enzymes for the liberation of nutrients 
from the host tissue. However, it became evident that 
bacterial proteolytic enzymes were acting in various ways to 
disrupt key host processes thereby aiding colonisation of 
hostile host tissue. They achieve this by several means such 
as activation of cascade pathways, disruption of cytokine 
signalling and inactivation of cell receptors and crucially via 
inactivation of host protease inhibitors [153]. During 
colonisation of the CF lung bacteria secrete numerous 
virulence factors including proteases which can regulate the 
inflammatory process. The opportunistic pathogen P. 
aeruginosa  also produces numerous virulence factors, 
several of which including the metalloelastase (LasB), are 
secreted outside the cell [154]. LasB has been shown to 
dampen the inflammatory response through the alteration of 
key membrane receptors such as the urokinase-type 
plasminogen activator receptor (uPAR) [155]. The 
proteolytic cleavage of uPAR by LasB results in a drastic 
reduction in the capacity of the cells to bind urokinase and 
loss of the ability of uPAR to interact with the matrix 
adhesive protein vitronectin thus altering the function of 
inflammatory cells during infection. P. aeruginosa LasB is 
also capable of cleaving similar substrates to those of NE 
and is known to cause tissue damage in the lung. 
  Another key virulence factor of P. aeruginosa is alginate 
exopolysaccaride which aids in the persistence of the 
organism in the CF lung. Alginate production is switched on 
primarily in the environment found in the CF lung and is 
only rarely encountered in other infections [156]. The 
importance of alginate as a virulence factor is highlighted by 
the correlation between alginate production and poor 
prognosis and high mortality of CF patients [11]. It has been 
shown that LasB is secreted in relatively high amounts by 
nonmucoid P. aeruginosa and conversely that it is reduced in 
mucoid alginate producing P. aeruginosa. This is thought to 
be in response to alginate production which requires 
intracellular LasB cleavage of nucleoside diphoshate kinase 
(NdK) from its 16 kDa from to a 12 kDa form for the 
generation of GTP which itself is required for the synthesis 
of alginate [154]. A LasB-specific inhibitor could target both 
the damaging effects of secreted LasB and crucially 
intracellular LasB thereby inhibiting biofilm formation. 
Therapies such as this in conjunction with antibiotics could 
lead to more effective clearance of colonising bacteria from 
the CF lung. The use of an antiprotease therapy to combat 
biofilm formation is especially attractive. Antiprotease 
therapy, unlike traditional antibiotics which target 
fundamental processes such as cell wall synthesis thereby 
creating enormous selection pressures, should be well 
tolerated and less likely to result in the generation of 
resistant pathogens [153]. 
CONCLUSIONS 
 In  conclusion,  evidence
  is accumulating to show that 
each protease family has a multitude
 of regulatory functions 
and may, either individually or as a component of one or 
more protease cascades, be of pivotal importance
  in CF. 
However, there is a need for further clarification as to the 
status, activity and integrity of such proteases and their 
endogenous inhibitors in CF lung disease. In CF, 
dysregulated protease activity results in upregulation of 
proinflammatory mediators, increased recruitment
  of 
inflammatory cells to the lung, impaired phagocytosis, 
increased
  mucin production, and inactivation of important 
innate and antimicrobial
  proteins resulting in sustained 
inflammation and predisposition
  to infection. One way to 
treat such protease-mediated events
 in chronic infective lung 
disease is with antiprotease therapy. Developing rational 
therapies, however, requires further identification of specific 
protease substrates and characterisation of the downstream 
consequences of protease activity in CF. In addition the 
identification and targeting of bacterial proteases involved in 
chronic infection processes such as the regulation of biofilm 
production would be a useful addition to CF therapeutic 
armoury. 
  Future research will also have to address the reasons for 
prolonged extracellular protease activity in CF compared 
with those conditions characterised by a shorter duration
 of 
protease activity, e.g. pneumonia. Because of
  the multiple 
protease activities present in CF, it may be important to 
identify definitively whether there
  is a key protease or 
proteases central to direct tissue destruction
 or activation of 
other proteases in the diseased lung, as suggested by a 
number of papers.
 Under these circumstances, neutralisation 
of one such protease
  with a specific antiprotease may be 
sufficient to lessen the
 overall protease burden in CF without
 
the need for inhibition of all proteases. 
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